Majority of rare diseases at present have none or little effective procedures of diagnosis & treatment, which can be partly attributed to absence of funding toward researches on rare disease pathogenesis and lack of representative patients. Rare neurological disease are among major types of rare diseases with ineffective diagnoses and treatment options. According to WHO, 1 in 10 individuals are expected to be diagnosed with rare neurological disorder in their lifetime. Brain diseases are considered to be one of the major determinants of the neurological disease prevalence worldwide, with early intervention being the only key to prevent or curtail long-term morbidity and relevant healthcare costs.
However, diagnosis of rare neurological diseases entails several barricades including lack of intelligence and awareness about such diseases within the common medical community. This has further resulted into delayed diagnosis, and sometimes misdiagnosis, as highlighted in the book about rare diseases compiled by European Organization for Rare Diseases (EURORDIS), co-funded by European Commission. According to the publication, patients suffering from rare neurological diseases experience challenges in accessing treatment services on the coattails of lack of referral.
Spreading awareness about these diseases along with increasing their visibility are key initiatives taken by various governments worldwide for speeding up diagnostic processes and provide affected families with access to proper counselling and treatment options.
A recently published report of Future Market Insights foresees the global rare neurological disease treatment market to record a spectacular growth between the period 2022 and 2032. Revenues from treatment of rare neurological disorders worldwide are poised to surpass US$ 19,795.14 Million by 2032-end.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In North America, rare neurological conditions are considered to a major healthcare concern, although fewer individuals are currently affected by the disease. Complexity of these diseases, along with their inadequacy in treatment options have led to disproportionate share of spending in healthcare. Drug companies in North America are conducting robust researches in rare diseases, however they face difficulties related to cost of treatment development related to small or geographically dispersed populations.
Government and healthcare institutes in North America are therefore collaborating to develop a robust research network, in order to facilitate data sharing, enrollment in trials & studies, and advancement in rare diseases. This will further influence the rare neurological disease treatment market in North America. The report estimates North America to remain the largest revenue contributor to the market.
Management of rare neurological diseases and provision of effective therapies represent an economic and social burden on several nations. Treatment options for patients affected with rare neurological conditions continue to be limited. Discrepancies in funding for Research and Development associated with treatment & prevention of these diseases is mainly linked with shortfall in the healthcare provision that reflects both shortage of material sources and suboptimal training exercises of clinicians apropos brain disorders.
Although there have been notable advancements in treatment of rare neurological diseases, these are not completely curative. Governments across the globe are therefore making significant improvements in their healthcare systems to render their management to be multidisciplinary, holistic, and to include supportive and palliative care. Establishing centers of expertise, which specialize in diagnosis, treatment & care of patients affected from rare neurological diseases, is a key focus area for most of the developed and developing countries across the globe.
Key players fuelling growth of the global rare neurological disease treatment market, as identified by the report, include Pfizer Inc., Allergan Plc, Novartis AG, Bayer Aktiengesellschaft, Medtronic Plc, Sanofi, Johnson & Johnson, and Teva Pharmaceutical Industries Limited.
Principal Consultant
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Rising awareness regarding the spread of neurological diseases fuels the market.
Significant improvement in the healthcare system boosts the market.
Novartis AG, Pfizer Inc., and Allergan Plc are the leading market players.
North America is dominating the industry.
The market is likely to surpass US$ 19.795 million by 2032.
1. Global Economic Outlook
2. Global Market - Executive Summary
3. Global Market Overview
3.1. Introduction
3.1.1. Global Market Taxonomy
3.1.2. Global Market Definition
3.2. Global Market Size (US$ Million) and Forecast, 2022 to 2032
3.2.1. Global Market Y-o-Y Growth
3.3. Global Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. USA, EU & Japan Orphan Designations per Year & Cumulative (2017 to 2021)
3.7. Worldwide Top 20 Orphan Drug Manufacturers (2022 to 2032)
3.8. Wheel of Fortune
3.9. Rare Disease Key Regulations
3.9.1. Rare Disease Key Regulations: North America
3.9.2. Rare Disease Key Regulations: Latin America
3.9.3. Rare Disease Key Regulations: Europe
3.9.4. Rare Disease Key Regulations: Asia Pacific
3.9.5. Rare Disease Key Regulations: Middle East & Africa
3.10. Forecast Scenario
3.11. PEST Analysis
3.12. Porte's Five Forces Analysis
3.13. Market Positioning and Behavioral Assessment
3.14. Investment Feasibility Assessment
3.15. Competitor Market Footprint Matrix
3.16. Key Participants Market Presence (Intensity Map) By Region
4. Global Market Analysis and Forecast 2022 to 2032
4.1. Global Market Size and Forecast By Indication, 2022 to 2032
4.1.1. Alzheimer’s Disease Market Size and Forecast, 2022 to 2032
4.1.1.1. Revenue (US$ Million) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Narcolepsy Market Size and Forecast, 2022 to 2032
4.1.2.1. Revenue (US$ Million) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Multiple Sclerosis Market Size and Forecast, 2022 to 2032
4.1.3.1. Revenue (US$ Million) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Amyotrophic Lateral Sclerosis Market Size and Forecast, 2022 to 2032
4.1.4.1. Revenue (US$ Million) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.1.5. Other Indications Market Size and Forecast, 2022 to 2032
4.1.5.1. Revenue (US$ Million) Comparison, By Region
4.1.5.2. Market Share Comparison, By Region
4.1.5.3. Y-o-Y growth Comparison, By Region
4.2. Global Market Size and Forecast By Drug Type, 2022 to 2032
4.2.1. Biologics Market Size and Forecast, 2022 to 2032
4.2.1.1. Revenue (US$ Million) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Organic Compounds Market Size and Forecast, 2022 to 2032
4.2.2.1. Revenue (US$ Million) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.3. Global Market Size and Forecast By Mode of Administration, 2022 to 2032
4.3.1. Injectable Market Size and Forecast, 2022 to 2032
4.3.1.1. Revenue (US$ Million) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Oral Market Size and Forecast, 2022 to 2032
4.3.2.1. Revenue (US$ Million) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Others Market Size and Forecast, 2022 to 2032
4.3.3.1. Revenue (US$ Million) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.4. Global Market Size and Forecast By Distribution Channel, 2022 to 2032
4.4.1. Hospital Pharmacies Market Size and Forecast, 2022 to 2032
4.4.1.1. Revenue (US$ Million) Comparison, By Region
4.4.1.2. Market Share Comparison, By Region
4.4.1.3. Y-o-Y growth Comparison, By Region
4.4.2. Retail Pharmacies Market Size and Forecast, 2022 to 2032
4.4.2.1. Revenue (US$ Million) Comparison, By Region
4.4.2.2. Market Share Comparison, By Region
4.4.2.3. Y-o-Y growth Comparison, By Region
4.4.3. Online Pharmacies Market Size and Forecast, 2022 to 2032
4.4.3.1. Revenue (US$ Million) Comparison, By Region
4.4.3.2. Market Share Comparison, By Region
4.4.3.3. Y-o-Y growth Comparison, By Region
5. North America Market Size and Forecast, 2022 to 2032
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Million) Comparison, By Country
5.4.1. USA Market Size and Forecast (US$ Million), 2022 to 2032
5.4.2. Canada Market Size and Forecast (US$ Million), 2022 to 2032
5.5. Revenue (US$ Million) Comparison, By Indication
5.6. Revenue (US$ Million) Comparison, By Drug Type
5.7. Revenue (US$ Million) Comparison, By Mode of Administration
5.8. Revenue (US$ Million) Comparison, By Distribution Channel
6. Latin America Market Size and Forecast, 2022 to 2032
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Million) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Million), 2022 to 2032
6.4.2. Mexico Market Size and Forecast (US$ Million), 2022 to 2032
6.4.3. Rest of Latin America Market Size and Forecast (US$ Million), 2022 to 2032
6.5. Revenue (US$ Million) Comparison, By Indication
6.6. Revenue (US$ Million) Comparison, By Drug Type
6.7. Revenue (US$ Million) Comparison, By Mode of Administration
6.8. Revenue (US$ Million) Comparison, By Distribution Channel
7. Europe Market Size and Forecast, 2022 to 2032
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Million) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Million), 2022 to 2032
7.4.2. United Kingdom Market Size and Forecast (US$ Million), 2022 to 2032
7.4.3. France Market Size and Forecast (US$ Million), 2022 to 2032
7.4.4. Spain Market Size and Forecast (US$ Million), 2022 to 2032
7.4.5. Italy Market Size and Forecast (US$ Million), 2022 to 2032
7.4.6. Rest of Europe Market Size and Forecast (US$ Million), 2022 to 2032
7.5. Revenue (US$ Million) Comparison, By Indication
7.6. Revenue (US$ Million) Comparison, By Drug Type
7.7. Revenue (US$ Million) Comparison, By Mode of Administration
7.8. Revenue (US$ Million) Comparison, By Distribution Channel
8. Japan Market Size and Forecast, 2022 to 2032
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Million), 2022 to 2032
8.5. Revenue (US$ Million) Comparison, By Indication
8.6. Revenue (US$ Million) Comparison, By Drug Type
8.7. Revenue (US$ Million) Comparison, By Mode of Administration
8.8. Revenue (US$ Million) Comparison, By Distribution Channel
9. APEJ Market Size and Forecast, 2022 to 2032
9.1. Asia Pacific Outlook
9.2. Asia Pacific Parent Market Outlook
9.3. Asia Pacific Target Market Outlook
9.4. Revenue (US$ Million) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Million), 2022 to 2032
9.4.2. India Market Size and Forecast (US$ Million), 2022 to 2032
9.4.3. Thailand Market Size and Forecast (US$ Million), 2022 to 2032
9.4.4. Singapore Market Size and Forecast (US$ Million), 2022 to 2032
9.4.5. Australia Market Size and Forecast (US$ Million), 2022 to 2032
9.4.6. Rest of APEJ Market Size and Forecast (US$ Million), 2022 to 2032
9.5. Revenue (US$ Million) Comparison, By Indication
9.6. Revenue (US$ Million) Comparison, By Drug Type
9.7. Revenue (US$ Million) Comparison, By Mode of Administration
9.8. Revenue (US$ Million) Comparison, By Distribution Channel
10. MEA Market Size and Forecast, 2022 to 2032
10.1. Middle East and Africa(MEA) Outlook
10.2. Middle East and Africa(MEA) Parent Market Outlook
10.3. Middle East and Africa(MEA) Target Market Outlook
10.4. Revenue (US$ Million) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Million), 2022 to 2032
10.4.2. South Africa Market Size and Forecast (US$ Million), 2022 to 2032
10.4.3. Nigeria Market Size and Forecast (US$ Million), 2022 to 2032
10.4.4. Rest of MEA Market Size and Forecast (US$ Million), 2022 to 2032
10.5. Revenue (US$ Million) Comparison, By Indication
10.6. Revenue (US$ Million) Comparison, By Drug Type
10.7. Revenue (US$ Million) Comparison, By Mode of Administration
10.8. Revenue (US$ Million) Comparison, By Distribution Channel
11. Global Market Company Share, Competition Landscape and Company Profiles
11.1. Global Market Company Share Analysis
11.2. Global Market Competition Landscape
11.3. Global Market Company Profiles
11.3.1. Pfizer Inc.
11.3.2. Allergan Plc
11.3.3. Novartis AG
11.3.4. Bayer Aktiengesellschaft
11.3.5. Medtronic Plc
11.3.6. Sanofi
11.3.7. Johnson & Johnson
11.3.8. Teva Pharmaceutical Industries Limited
11.3.9. Jazz Pharmaceuticals
11.3.10. EMD Serono, Inc.
12. Key Takeaways
13. Research Methodology
14. Disclaimer
Explore Healthcare Insights
View Reports
Rare Neurological Disease Treatment Market
